Novel Immunosuppressant Shows Promise in Kidney Transplant Patients

A recent Phase 2 clinical trial indicates that the novel anti-CD40L antibody therapy known as tegoprubart may offer superior kidney function preservation and improved quality of life compared to standard immunosuppressive regimens in adults receiving their first kidney transplant.

Phase 2 Trial Findings

The BESTOW clinical trial evaluated tegoprubart against tacrolimus, which currently serves as the standard of care for immunosuppression in transplant recipients. Findings from the study showed that kidney graft function stabilized following the first month of treatment. Furthermore, function remained higher in patients treated with tegoprubart than in those receiving tacrolimus across evaluated time points, achieving a statistically significant benefit at the 18-month mark.

Researchers also analyzed patient-reported health-related quality of life outcomes. Among 127 initially treated participants, 107 individuals finished the study treatment through week 52. Evaluations revealed improvements from baseline at week 52 across all five subscales for participants taking tegoprubart, compared to four out of five subscales for the tacrolimus group.

Potential Benefits Over Standard Care

Additional observations from the trial data included greater improvements on a mental component summary for patients receiving tegoprubart. These participants also experienced a numerically greater reduction in total symptom scores from baseline.

Corresponding author Andrew Adams, MD, PhD, of the University of Minnesota Medical School, noted that while current tacrolimus treatments help prevent organ rejection, they often introduce significant side effects such as kidney toxicity, hypertension, diabetes, tremors, and cognitive difficulties commonly referred to as brain fog. Dr. Adams explained that tegoprubart targets the CD40L pathway, which is central to immune cell communication, pointing to its potential to replace standard therapies and reduce side effects across transplant types.

Next Steps and Considerations

The findings are scheduled to be presented at ASN Kidney Week. While the Phase 2 results offer encouraging data regarding rejection prevention and symptom reduction without traditional adverse effects, researchers emphasize that further investigation in larger clinical trials is necessary to confirm these benefits and establish long-term safety profiles for broader transplant applications.

• Evaluated tegoprubart against tacrolimus in a Phase 2 clinical trial
• Demonstrated statistically significant kidney function benefit at 18 months
• Showed improvements in patient-reported quality of life and mental component summaries